Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $6.4 million.

  • Fulcrum Therapeutics' Accumulated Expenses fell 2287.02% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 2287.02%. This contributed to the annual value of $7.7 million for FY2024, which is 1182.67% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Accumulated Expenses of $6.4 million as of Q3 2025, which was down 2287.02% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Accumulated Expenses registered a high of $12.5 million during Q2 2022, and its lowest value of $4.4 million during Q1 2025.
  • Over the past 5 years, Fulcrum Therapeutics' median Accumulated Expenses value was $7.7 million (recorded in 2024), while the average stood at $7.6 million.
  • In the last 5 years, Fulcrum Therapeutics' Accumulated Expenses skyrocketed by 6315.58% in 2022 and then plummeted by 3684.84% in 2023.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Accumulated Expenses stood at $9.2 million in 2021, then increased by 3.47% to $9.6 million in 2022, then fell by 8.64% to $8.7 million in 2023, then decreased by 11.83% to $7.7 million in 2024, then fell by 16.45% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $4.9 million for Q2 2025, and $4.4 million during Q1 2025.